Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

Simple Summary The maintenance of the structural integrity of therapeutic proteins in the target tissue is crucial to their proper function. In this study, we aimed to assess the in vivo stability of the therapeutic protein Omomyc in blood serum and tumor tissue in a xenograft mouse model of colorectal cancer. As Omomyc represents a new clinical modality to target MYC, a most wanted target found deregulated in the majority of human cancers, our findings provide grounds to support the administration regimen in solid tumors. Moreover, we show that this method could apply to paraffin-embedded clinical biopsies for direct protein detection in patient samples. MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum.

Automated summary

The in vivo stability of therapeutic protein Omomyc was assessed in blood serum and tumor tissue. The results showed that the functional integrity of Omomyc remained preserved in the tumor tissue for at least 72 hours following administration and exhibited superior pharmacokinetics in the tumor compartment compared with blood serum. Therefore, Omomyc can be considered as an effective therapeutic agent.